The Palo Alto, California-based company laif off 33 employees in June and another 67 in November.
The June moves included delaying a late-stage clinical trial of a restless legs syndrome treatment and mid-stage work on an epilepsy and bipolar disorder treatment.
Jazz will take a $1.9 million layoff-related charge in the fourth quarter.
CFO Matt Fust is leaving the company to pursue “other professional interests,” the company said.